Potential risks include: Enhanced gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) Increased risk of nutritional deficiencies and protein malnutrition Potential worsening of gastroesophageal reflux symptoms Dehydration risk and acute kidney injury, particularly during dose escalation Increased risk of gallbladder disease and complications Risk of intestinal obstruction or ileus Diabetic retinopathy progression in patients with diabetes, particularly with rapid glycemic improvement Hypoglycemia risk, particularly in patients on insulin or sulfonylureas Cost considerations and insurance coverage challenges Rare but serious risks including pancreatitis and thyroid C-cell tumors (boxed warning) Clinicians must engage in shared decision-making with patients, carefully weighing these potential benefits against risks in the context of individual patient circumstances, surgical outcomes, comorbidities, and treatment goals
Two pivotal readouts are now public one in obesity with knee osteoarthritis, one in type 2 diabetes and seven additional Phase 3 readouts are expected before the end of 2026
Biochemistry 59 , 240249 (2020)
[DOI] [PMC free article] [PubMed] [Google Scholar] 101.Sndergrd S.D., Cintin I., Kuhlman A.B., Morville T.H., Bergmann M.L., Kjr L.K., Poulsen H.E., Giustarini D., Rossi R., Dela F., et al
Cyanocobalamin contains a cyanide group attached to the cobalamin molecule
Rated 4.6/5 by 70 verified customers 5MG Ships Monday morning if ordered within 39 hrs 21 min
